950220 — Neoimmunetech Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩115bn
- KR₩91bn
- $0.12m
Annual cashflow statement for Neoimmunetech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.8 | -45.9 | -46.8 | -40.9 | -30 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.05 | 9.43 | 6.09 | 2.86 | 1.08 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.71 | 6.26 | 5 | -3.03 | -2.43 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -26.6 | -28.6 | -33.5 | -38.6 | -28.6 |
| Capital Expenditures | -0.999 | -2.29 | -1.95 | -0.614 | -1.14 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 4.83 | -0.944 | -0.532 | 2.23 | -7.35 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3.83 | -3.23 | -2.49 | 1.62 | -8.48 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.029 | 97 | -0.5 | -0.881 | 8.22 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -22.8 | 64.7 | -38.9 | -37.9 | -30.1 |